PSB-201

N/A

Report date: 2025/03/26 15:00:46

Base Information

Drug NamePSB-201

Drug Alias NameHeterodimeric bispecific antibodiesbifunctional antibody therapy MabPairPSB-201

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesQilu Puget Sound Biotherapeutics Corp

China Registration ClassN/A

Develop Information

Active CompaniesQilu Puget Sound Biotherapeutics Corp

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A